Liver Disease
News
Interferon-free regimen cures 100% of hard-to-treat hepatitis C
Major finding: Sustained virological response rates 12 weeks posttreatment were 100% in treatment-naive and prior null responders.Data source: In...
News
Obesity, diabetes fuel liver disease epidemic
News
Review: Interferon therapy for hepatitis C offers little benefit
Major Finding: The risk of all-cause mortality among hepatitis C patients receiving interferon monotherapy after not responding to prior treatment...
From the AGA Journals
Statins cut risk of hepatocellular carcinoma
Major Finding: Statin therapy reduced the risk of developing hepatocellular carcinoma by 37% overall; the risk reduction was stronger (48%) in...
News
New interferon gene identified
Major Finding: Upstream of IFNL3 on chromosome 19q13.13, researchers located a new interferon gene, IFNL4, which is associated with impaired...
From the AGA Journals
Futility rules defined for telaprevir-based HCV therapy
Major Finding: Telaprevir, peginterferon, and ribavirin for the treatment of hepatitis C should be stopped in both treatment-naive and treatment-...
Conference Coverage
Interferon plus entecavir may tame chronic HBV
Major Finding: Patients with chronic hepatitis B who were treated with entecavir and pegylated interferon alfa-2a had a greater decline in HBV DNA...
Conference Coverage
Ribavirin dose reduction, erythropoietin combat HCV anemia
Major Finding: In cirrhotic and noncirrhotic patients treated with boceprevir, pegylated interferon alfa-2b, and ribavirin, 57% of patients with...
Conference Coverage
Avatrombopag reduces preprocedure platelet needs in chronic liver disease
Major Finding: In a study cohort with a second-generation formulation of avatrombopag, 9 of 21 patients on a 10-mg daily dose (42.9%) had a...
Conference Coverage
Tenofovir alone suffices against lamivudine-resistant hepatitis B
Major Finding: In a phase IIIb randomized study, 89% of lamivudine-resistant patients with HBV who received tenofovir alone met the primary end...